Melanoma Clinical Trials in Salt Lake City

Showing 81-100 of 244 trials

A Study to Investigate LYL845 in Adults With Solid Tumors

NCT05573035

This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).

MelanomaNon-small Cell Lung CancerColorectal Cancer

Lyell Immunopharma, Inc.39 participantsStarted Dec 2022

Sacramento, California, United States • Santa Monica, California, United States • Stanford, California, United States +15 more locations

Active Not RecruitingPhase 1/2< 1 mile

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

Non Small Cell Lung CancerAdvanced Solid TumorMetastatic Melanoma+16 more

OncoC4, Inc.733 participantsStarted Sep 2020

Springdale, Arkansas, United States • Davis, California, United States • Downey, California, United States +34 more locations

A Study to Investigate LYL845 in Adults With Solid Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Melanoma Trials in Other Cities

Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

MGC018 With or Without MGA012 in Advanced Solid Tumors

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

A Study of SEA-CD40 Given With Other Drugs in Cancers

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

Other Conditions in Salt Lake City